Comparative Pharmacology
Head-to-head clinical analysis: PREDNISOLONE TEBUTATE versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREDNISOLONE TEBUTATE versus STERANE.
PREDNISOLONE TEBUTATE vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell activity.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
20-60 mg intramuscularly or intra-articularly once daily as a single dose or divided every 6-12 hours; dose varies by indication and severity.
100 mg orally every 12 hours
None Documented
None Documented
Terminal half-life: 2-4 hours (plasma); clinical effects persist longer (18-36 hours) due to prolonged receptor occupancy and transcriptional effects.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal: primarily as metabolites, <20% unchanged; small fecal/biliary contribution.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category D/X
Category C
Corticosteroid
Corticosteroid